This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Chatham, W W Articles by Kimberly, R P Search for Related Content PubMed PubMed Citation Articles by Chatham, W W Articles by Kimberly, R P Social Bookmarking                         What's this?

Treatment of lupus with corticosteroids

The University of Alabama at Birmingham, Birmingham, Alabama, USA; Division of Clinical and Immunology and Rheumatology, THT 437, 1530 3rd Avenue South, Birmingham, AL 35294, USA,Winn.Chatham{at}ccc.uab.edu

R P Kimberly

The University of Alabama at Birmingham, Birmingham, Alabama, USA

Through direct signals to the nucleus mediated by the glucocorticoid receptor, exogenous glucocorticoids impact a broad array of cellular functions. DNA binding of the glucocorticoid receptor, depending upon the specific promoter to which the receptor binds, affects gene expression by recruiting transcription factors to the promoter or by interfering with the function of co-factors required for gene transcription. Steroid effects on the adhesion functions and release of products by phagocytic cells are prompt, occurring within hours of administration. Administration of corticosteroids results in rapid depletion of circulating T-cells due to a combination of effects including enhanced circulatory emigration, induction of apoptosis, inhibition of T-cell growth factors, and impaired release of cells from lymphoid tissues. Corticosteroid effects on B-cell function and immunoglobulin production are more delayed. The broad, generally suppressive effects of corticosteroids on the immune response render them useful for the management of most organ system manifestations of lupus. Corticosteroid toxicity in lupus is notable for greater susceptibility to infections, osteoporosis, osteonecrosis and accelerated atherogenesis. Although use of corticosteroids for patients with severe disease manifestations is associated with higher numbers of deaths from infections, overall survival appears to be improved.

Key Words: lupus • corticosteroids

Lupus, Vol. 10, No. 3, 140-147 (2001)
DOI: 10.1191/096120301675075008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Uppal, S. Hayat, and R Raghupathy Efficacy and safety of infliximab in active SLE: a pilot study Lupus, July 1, 2009; 18(8): 690 - 697. [Abstract] [PDF]

				I. Tatsuno, T. Sugiyama, S. Suzuki, T. Yoshida, T. Tanaka, M. Sueishi, and Y. Saito Age Dependence of Early Symptomatic Vertebral Fracture with High-Dose Glucocorticoid Treatment for Collagen Vascular Diseases J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1671 - 1677. [Abstract] [Full Text] [PDF]

				C. Mok, C. To, and K. Ma Changes in body composition after glucocorticoid therapy in patients with systemic lupus erythematosus Lupus, November 1, 2008; 17(11): 1018 - 1022. [Abstract] [PDF]

				C B Driver, M Ishimori, and M H Weisman The B cell in systemic lupus erythaematosus: a rational target for more effective therapy Ann Rheum Dis, October 1, 2008; 67(10): 1374 - 1381. [Abstract] [Full Text] [PDF]

				M. A. Kamal and W. J. Jusko Interactions of Prednisolone and Other Immunosuppressants Used in Dual Treatment of Systemic Lupus Erythematosus in Lymphocyte Proliferation Assays J. Clin. Pharmacol., September 1, 2004; 44(9): 1034 - 1045. [Abstract] [Full Text] [PDF]

				W. Matsuyama, M. Yamamoto, I. Higashimoto, K.-i. Oonakahara, M. Watanabe, K. Machida, T. Yoshimura, N. Eiraku, M. Kawabata, M. Osame, et al. TNF-related apoptosis-inducing ligand is involved in neutropenia of systemic lupus erythematosus Blood, July 1, 2004; 104(1): 184 - 191. [Abstract] [Full Text] [PDF]

				M Sayarlioglu, M Inanc, S Kamali, A Cefle, O Karaman, A Gul, L Ocal, O Aral, and M Konice Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization Lupus, April 1, 2004; 13(4): 274 - 278. [Abstract] [PDF]

				G Sanna, M L Bertolaccini, and A Mathieu Central nervous system lupus: a clinical approach to therapy Lupus, December 1, 2003; 12(12): 935 - 942. [Abstract] [PDF]

				M J Cuadrado and G Sanna Headache and systemic lupus erythematosus Lupus, December 1, 2003; 12(12): 943 - 946. [Abstract] [PDF]

				J. C. Luo, V. Y. Shin, E. S. L. Liu, W. H. L. So, Y. N. Ye, F. Y. Chang, and C. H. Cho Non-Ulcerogenic Dose of Dexamethasone Delays Gastric Ulcer Healing in Rats J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 692 - 698. [Abstract] [Full Text] [PDF]

				F Lopez-Medrano, R Cervera, O Trejo, J Font, and M Ingelmo Steroid induced psychosis in systemic lupus erythematosus: a possible role of serum albumin level Ann Rheum Dis, June 1, 2002; 61(6): 562 - 563. [Full Text] [PDF]